Jiri Minarik1, Tomas Pika2, Jakub Radocha3, Alexandra Jungova4, Jan Straub5, Tomas Jelinek6, Ludek Pour7, Petr Pavlicek8, Martin Mistrik9, Lucie Brozova10, Petra Krhovska2, Katerina Machalkova3, Pavel Jindra4, Ivan Spicka5, Hana Plonkova6, Martin Stork7, Jaroslav Bacovsky2, Lenka Capkova10, Michal Sykora11, Petr Kessler12, Lukas Stejskal13, Adriana Heindorfer14, Jana Ullrychova15, Tomas Skacel16,17, Vladimir Maisnar3, Roman Hajek6. 1. Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic. abretina@email.cz. 2. Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic. 3. 4th Department of Internal Medicine - Hematology, Faculty Hospital and Charles University in Hradec Kralove, Hradec Kralove, Czech Republic. 4. Hematology and Oncology Department, Charles University Hospital Pilsen, Pilsen, Czech Republic. 5. 1st Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic. 6. Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic. 7. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic. 8. Department of Internal Medicine and Hematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic. 9. Department of Hematology and Transfusiology, Faculty of Medicine, University Hospital Bratislava, Bratislava, Slovakia. 10. Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic. 11. Department of Clinical Hematology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic. 12. Department of Hematology and Transfusion Medicine, Hospital Pelhrimov, Pelhrimov, Czech Republic. 13. Department of Hematology, Silesian Hospital in Opava, Opava, Czech Republic. 14. Department of Hematology, Hospital Liberec, Liberec, Czech Republic. 15. Department of Clinical Hematology, Regional Health Corporation, Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic. 16. 1st Department of Medicine, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic. 17. Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Abstract
BACKGROUND: We have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice. METHODS: A total of 344 patients treated with IRD (N = 127) or RD (N = 217) were selected for analysis from the Czech Registry of Monoclonal Gammopathies (RMG). Descriptive statistics were used to assess patient's characteristics associated with the respective therapy. The primary endpoint was progression free survival (PFS), secondary end points included response rates and overall survival (OS). Survival endpoints were plotted using Kaplan-Meier methodology at 95% Greenwood confidence interval. Univariable and multivariable Cox proportional hazards models were used to evaluate the effect of treatment regimens and the significance of uneven variables. Statistical tests were performed at significance level 0.05. RESULTS: In the whole cohort, median PFS for IRD was 17.5 and for RD was 11.5 months favoring the all-oral triplet, p = 0.005; in patients within relapse 1-3, the median PFS was 23.1 vs 11.6 months, p = 0.001. The hazard ratio for PFS was 0.67 (95% confidence interval [CI] 0.51-0.89, p = 0.006). The PFS advantage translated into improved OS for patients treated with IRD, median 36.6 months vs 26.0 months (p = 0.008). The overall response rate (ORR) was 73.0% in the IRD group vs 66.2% in the RD group with a complete response rate (CR) of 11.1% vs 8.8%, and very good partial response (VGPR) 22.2% vs 13.9%, IRD vs RD respectively. The IRD regimen was most beneficial in patients ≤75 years with ISS I, II, and in the first and second relapse. Patients with the presence of extramedullary disease did not benefit from IRD treatment (median PFS 6.5 months). Both regimens were well tolerated, and the incidence of total as well as grade 3/4 toxicities was comparable. CONCLUSIONS: Our analysis confirms the results of the TOURMALINE-MM1 study and shows benefit of all-oral triplet IRD treatment versus RD doublet. It demonstrates that the addition of ixazomib to RD improves key survival endpoints in patients with RRMM in a routine clinical setting.
BACKGROUND: We have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice. METHODS: A total of 344 patients treated with IRD (N = 127) or RD (N = 217) were selected for analysis from the Czech Registry of Monoclonal Gammopathies (RMG). Descriptive statistics were used to assess patient's characteristics associated with the respective therapy. The primary endpoint was progression free survival (PFS), secondary end points included response rates and overall survival (OS). Survival endpoints were plotted using Kaplan-Meier methodology at 95% Greenwood confidence interval. Univariable and multivariable Cox proportional hazards models were used to evaluate the effect of treatment regimens and the significance of uneven variables. Statistical tests were performed at significance level 0.05. RESULTS: In the whole cohort, median PFS for IRD was 17.5 and for RD was 11.5 months favoring the all-oral triplet, p = 0.005; in patients within relapse 1-3, the median PFS was 23.1 vs 11.6 months, p = 0.001. The hazard ratio for PFS was 0.67 (95% confidence interval [CI] 0.51-0.89, p = 0.006). The PFS advantage translated into improved OS for patients treated with IRD, median 36.6 months vs 26.0 months (p = 0.008). The overall response rate (ORR) was 73.0% in the IRD group vs 66.2% in the RD group with a complete response rate (CR) of 11.1% vs 8.8%, and very good partial response (VGPR) 22.2% vs 13.9%, IRD vs RD respectively. The IRD regimen was most beneficial in patients ≤75 years with ISS I, II, and in the first and second relapse. Patients with the presence of extramedullary disease did not benefit from IRD treatment (median PFS 6.5 months). Both regimens were well tolerated, and the incidence of total as well as grade 3/4 toxicities was comparable. CONCLUSIONS: Our analysis confirms the results of the TOURMALINE-MM1 study and shows benefit of all-oral triplet IRD treatment versus RD doublet. It demonstrates that the addition of ixazomib to RD improves key survival endpoints in patients with RRMM in a routine clinical setting.
Authors: Sagar Lonial; Meletios Dimopoulos; Antonio Palumbo; Darrell White; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Philippe Moreau; Maria-Victoria Mateos; Hila Magen; Andrew Belch; Donna Reece; Meral Beksac; Andrew Spencer; Heather Oakervee; Robert Z Orlowski; Masafumi Taniwaki; Christoph Röllig; Hermann Einsele; Ka Lung Wu; Anil Singhal; Jesus San-Miguel; Morio Matsumoto; Jessica Katz; Eric Bleickardt; Valerie Poulart; Kenneth C Anderson; Paul Richardson Journal: N Engl J Med Date: 2015-06-02 Impact factor: 91.245
Authors: Shaji K Kumar; Betsy R LaPlant; Craig B Reeder; Vivek Roy; Alese E Halvorson; Francis Buadi; Morie A Gertz; P Leif Bergsagel; Angela Dispenzieri; Melanie A Thompson; Jamie Crawley; Prashant Kapoor; Joseph Mikhael; Keith Stewart; Suzanne R Hayman; Yi L Hwa; Wilson Gonsalves; Thomas E Witzig; Sikander Ailawadhi; David Dingli; Ronald S Go; Yi Lin; Candido E Rivera; S Vincent Rajkumar; Martha Q Lacy Journal: Blood Date: 2016-10-04 Impact factor: 22.113
Authors: Paul G Richardson; Wanling Xie; Sundar Jagannath; Andrzej Jakubowiak; Sagar Lonial; Noopur S Raje; Melissa Alsina; Irene M Ghobrial; Robert L Schlossman; Nikhil C Munshi; Amitabha Mazumder; David H Vesole; Jonathan L Kaufman; Kathleen Colson; Mary McKenney; Laura E Lunde; John Feather; Michelle E Maglio; Diane Warren; Dixil Francis; Teru Hideshima; Robert Knight; Dixie-Lee Esseltine; Constantine S Mitsiades; Edie Weller; Kenneth C Anderson Journal: Blood Date: 2014-01-15 Impact factor: 22.113
Authors: Philippe Moreau; Tamás Masszi; Norbert Grzasko; Nizar J Bahlis; Markus Hansson; Ludek Pour; Irwindeep Sandhu; Peter Ganly; Bartrum W Baker; Sharon R Jackson; Anne-Marie Stoppa; David R Simpson; Peter Gimsing; Antonio Palumbo; Laurent Garderet; Michele Cavo; Shaji Kumar; Cyrille Touzeau; Francis K Buadi; Jacob P Laubach; Deborah T Berg; Jianchang Lin; Alessandra Di Bacco; Ai-Min Hui; Helgi van de Velde; Paul G Richardson Journal: N Engl J Med Date: 2016-04-28 Impact factor: 91.245
Authors: J Bladé; D Samson; D Reece; J Apperley; B Björkstrand; G Gahrton; M Gertz; S Giralt; S Jagannath; D Vesole Journal: Br J Haematol Date: 1998-09 Impact factor: 6.998
Authors: David S Siegel; Meletios A Dimopoulos; Heinz Ludwig; Thierry Facon; Hartmut Goldschmidt; Andrzej Jakubowiak; Jesus San-Miguel; Mihaela Obreja; Julie Blaedel; A Keith Stewart Journal: J Clin Oncol Date: 2018-01-17 Impact factor: 44.544
Authors: Paul G Richardson; Jesus F San Miguel; Philippe Moreau; Roman Hajek; Meletios A Dimopoulos; Jacob P Laubach; Antonio Palumbo; Katarina Luptakova; Dorothy Romanus; Tomas Skacel; Shaji K Kumar; Kenneth C Anderson Journal: Blood Cancer J Date: 2018-11-09 Impact factor: 11.037
Authors: Gergely Varga; Zsolt Nagy; Judit Demeter; Szabolcs Kosztolányi; Árpád Szomor; Hussain Alizadeh; Beáta Deák; Tamás Schneider; Márk Plander; Tamás Szendrei; László Váróczy; Árpád Illés; Árpád Bátai; Mónika Pető; Gábor Mikala Journal: Pathol Oncol Res Date: 2019-02-02 Impact factor: 3.201
Authors: Martin Stork; Sabina Sevcikova; Jiri Minarik; Petra Krhovska; Jakub Radocha; Lenka Pospisilova; Lucie Brozova; Jiri Jarkovsky; Ivan Spicka; Jan Straub; Petr Pavlicek; Alexandra Jungova; Tomas Jelinek; Viera Sandecka; Vladimir Maisnar; Roman Hajek; Ludek Pour Journal: Br J Haematol Date: 2021-11-02 Impact factor: 8.615